Status:
COMPLETED
Evaluation of the Effects of Simvastatin 40mg
Lead Sponsor:
Cardinal Tien Hospital
Conditions:
Hypercholesterolemia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To collect lipid-lowering response data with the use of simvastatin 40 mg tablet in patients with hypercholesterolemia.
Detailed Description
This is an open-label, prospective study to investigate lipid-lowering efficacy and sympathetic response of normotensive hypercholesterolemia patients after receiving simvastatin 40 mg once daily for ...
Eligibility Criteria
Inclusion
- Male or female patient, \>18 years of age
- Patients with hypercholesterolemia who meet the following lipid criteria:
- primary cholesterolemia: total cholesterol\>=240 mg/dl or ldl-c \>= 160 mg/dl
- secondary cholesterolemia (patients with cad, dm): ldl-c\>=130 mg/dl
- The patient is willing to follow an NCEP therapeutic lifestyle changes (tlc) or similar cholesterol-lowering diet throughout the duration of the study
Exclusion
- Congestive heart failure (NYHA class III or IV), uncontrolled cardiac arrhythmia, unstable angina
- Hypertension (based on the atp 3 guidelines)
- Taking potent lipid-lowering agents
- Unstable diabetes (hba1c \>9%) or newly diagnosed (within 3 months), or a change in anti-diabetes medications within 3 months of screening
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00397826
Start Date
January 1 2005
End Date
December 1 2015
Last Update
January 7 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.